Cure Brain Cancer Neuro-Oncology Group
Glioblastoma (GBM) is the most common brain cancer with a median survival of only 15 months. Infiltration, cell migration and resistance to chemotherapy and radiotherapy are characteristic of GBM. As new therapeutic regimes are developed, it is paramount that we work out a strategy for identifying the patients that will show a positive response to treatment.
The discovery of new biomarkers with capacity to predict patient response to treatment is a key priority of the Cure Brain Cancer Neuro-oncology Group. Understanding the mechanisms of tumour migration and infiltration is another research priority for the group.
Information on the Cure Brain Cancer Foundation can be found here.
Grants & Funding
McDonald (PI), Combining microRNA with cilengitide: A novel therapeutic approach to impede brain tumour cell migration. Cancer Institute NSW Career Development Fellowship, 2010-2013
McDonald (PI), The role of IQGAP1 in actively migrating glioma cells and its regulation by miR-124. Cancer Council NSW Project Grant, 2009-2011
McDonald (Co-PI), Clinical Outcomes and Genetic Epidemiology of High Grade Glioma: AGOG. Cancer Council NSW Strategic Partnership Grant, 2008-2012
Investigating AngioMiRs and the role they play in anti-angiogenic therapy resistance in brain cancer
Brain cancers are highly angiogenic. Patients show modest response to anti-angiogenic chemotherapies such as avastin, thalidomide and cilengitide. Unfortunately, in response to specific anti-VEGF inhibitors, patients are not only showing a strong acquired resistance but the tumour behaviour is much more aggressive. This heightened response may be in part due to hypoxia. Regulation of microRNAs in hypoxic conditions has not been well studied. This project would examine the change in microRNA expression profiles in brain cancer cells grown in normoxic and hypoxic conditions and their role in angiogenesis regulation assessed.
Applicants should contact Dr Kerrie McDonald email@example.com for more information and application forms.
Contact: Associate Professor Kerrie McDonald